Brief: Surface Oncology To Present SRF388 And SRF114 Preclinical Data At Upcoming Society For Immunotherapy For Cancer 2020 Conference
09/11/2020 14:45
Nov 9 (Reuters) - Surface Oncology Inc SURF.O :
* SURFACE ONCOLOGY TO PRESENT SRF388 AND SRF114 PRECLINICAL
DATA
AT UPCOMING SOCIETY FOR IMMUNOTHERAPY FOR CANCER 2020 VIRTUAL
CONFERENCE
* SURFACE ONCOLOGY INC - TARGETING CCR8 WITH SRF114 CAUSES
DEPLETION OF INTRA-TUMORAL TREGS
* SURFACE ONCOLOGY INC - SRF114 IS HIGHLY SELECTIVE FOR
CCR8; NO
OFF-TARGET BINDING WAS IDENTIFIED
* SURFACE ONCOLOGY INC - IDENTIFIED A POTENTIAL BIOMARKER
ASSOCIATED WITH IL-27
Source text for Eikon: ID:nGNX9kVw2g
Further company coverage: SURF.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Surface Oncology
See all newsBrief: Surface Oncology Says Anticipates Will Have Net Cash Of $20 Million To $25 Million At The Closing Of The Proposed Mergers
Surface Oncology Inc reports results for the quarter ended in June - Earnings Summary
Brief: Surface Oncology, Inc. Q2 Net Income USD -28.2 Mln
Surface Oncology Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: ADAR1 Partners Reports 5.24% Passive Stake In Surface Oncology Inc As Of July 10 - SEC Filing